InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
61,100.96
(
0.50%
)
Post# of 105534
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Edward

Send PM Follow Ignore
Followers 37
Posts 6385
Boards Moderated 3
Alias Born 05/06/2014

Edward

Re: tradinguru post# 99536

Wednesday, 05/25/2016 12:33:48 PM

Wednesday, May 25, 2016 12:33:48 PM

Post# of 105534
The 300 samples is an estimate based on actual numbers reported to the SEC for the 1st quarter 2016.The reasoning was explained and posted twice. CBAI states how much of the revenues are recurring, leaving the remainder for new accounts. Rational determination and straight forward. The one time fee for a new a account is clear $975. Since they have lost most of there tissue sales there are appox. 300 new customers for cord blood .

What is the basis for the accusation that there is under the table payments based on? Can't wait for the SEC report, probably won't live another 100 years.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up